Biomarkers of residual disease after neoadjuvant therapy for breast cancer

@article{PenaultLlorca2016BiomarkersOR,
  title={Biomarkers of residual disease after neoadjuvant therapy for breast cancer},
  author={Fr{\'e}d{\'e}rique Penault-Llorca and Nina Radosevic-Robin},
  journal={Nature Reviews Clinical Oncology},
  year={2016},
  volume={13},
  pages={487-503}
}
Nowadays, the decision of which adjuvant treatment should be given to patients with residual breast cancer after neoadjuvant therapy is based on the initial, pretreatment breast cancer molecular subtype and on the estimated residual tumour burden after neoadjuvant therapy. Substantial biological differences exist, however, between treatment-naive breast cancer and the residual tissue that remains after neoadjuvant therapy. In addition, the evaluation of relapse risk in patients is subject to a… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 9 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

Similar Papers

Loading similar papers…